FAQ on TransCode Therapeutics' Appointment of RNAi Pioneer Phillip Zamore to Scientific Advisory Board
Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Dr. Phillip D. Zamore, a renowned RNA interference (RNAi) researcher, to its Scientific Advisory Board, enhancing its RNA-targeted cancer therapy programs.
Who is Dr. Phillip D. Zamore?
Dr. Phillip D. Zamore is a leading figure in RNA interference (RNAi) research, co-founder of Alnylam Pharmaceuticals, and currently the Chair of the RNA Therapeutics Institute at UMass Chan Medical School. His foundational work in RNA biology and gene silencing mechanisms has earned him election to the National Academy of Sciences.
Why is Dr. Zamore’s appointment significant for TransCode Therapeutics?
Dr. Zamore’s appointment is a strategic enhancement to TransCode Therapeutics’ RNA-targeted cancer therapy programs, leveraging his expertise in RNA biology and gene silencing to advance the company’s oncology research and development efforts.
What is TransCode Therapeutics’ focus?
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
What is TransCode Therapeutics’ lead therapeutic candidate?
TransCode’s lead therapeutic candidate is TTX-MC138, aimed at treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis.
Where can I find more information about TransCode Therapeutics?
More information about TransCode Therapeutics (NASDAQ: RNAZ) is available in the company’s newsroom at https://ibn.fm/RNAZ.
What is the significance of RNA interference (RNAi) in cancer therapy?
RNA interference (RNAi) plays a crucial role in cancer therapy by enabling the silencing of specific genes involved in cancer progression, offering a targeted approach to treat cancers with minimal side effects compared to traditional therapies.
How does TransCode Therapeutics plan to overcome RNA delivery challenges?
TransCode Therapeutics aims to overcome RNA delivery challenges through its proprietary TTX nanoparticle platform, designed to effectively deliver RNA therapeutics to target cancer cells, unlocking access to novel genetic targets relevant to treating various cancers.
Where can I view the full press release about Dr. Zamore’s appointment?
The full press release can be viewed at https://ibn.fm/ZAIZp.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 111290